Virus-Like Particles Market Worth US$ 9.80 Billion by 2031 - Growth Plus Reports

Newark, New Castle, USA, June 19, 2023 (GLOBE NEWSWIRE) -- According to a new analysis by Growth Plus Reports, the global virus-like particles market is estimated to be worth US$ 9.80 billion by 2031, with a revenue CAGR of 7.85%. The study examines the key strategies, factors and prospects, competitive landscape, evolving industry patterns, market size, financial information and forecasts, and potential business opportunities.

Key Takeaways:

• Increasing research and development will drive market growth.
• Increasing demand for virus-like particles-based vaccines will support market revenue growth.
• North America will dominate the global market with the largest revenue share.

Get a Free Sample Research Report: https://www.growthplusreports.com/inquiry/request-sample/viruslike-particles-market/8493

                                                    Virus-like Particles Market Scope

Market Drivers
Increased demand for virus-like particles-based vaccines is the primary factor driving the revenue growth of the virus-like particles market. Furthermore, increased use of virus-like particles as delivery systems for gene editing and increasing research and development on vaccines based on these particles is expected to contribute to market revenue growth. Besides this, the high efficacy of virus-like particles in treating genetic diseases and developing new therapies will boost market revenue growth. 

Market Segmentation
Growth Plus Reports has analyzed the global virus-like particles market from four perspectives: Type, Source, Application, and Region.

Type Segmentation: Based on the material, the virus-like particles market is segmented into vaccines and therapeutics. The vaccine segment dominates the market with the largest revenue share because of vaccinations with virus-like particles have a successful track record and are safe and immunogenic by nature.

Source Segmentation: Based on the source, the virus-like particles market is segmented into yeast, plant, insect cell, and others. The yeast segment dominates the market with the largest revenue share because yeast offers benefits such scalable fermentation, reduced risk of contamination by organisms, affordable manufacturing, and the ability to produce VLPs of a high quality.

Application Segmentation: Based on the application, the virus-like particles market is segmented into hepatitis, Gaucher disease, cancer/HPV, and others. The hepatitis segment dominates the market with the largest revenue share because of VLPs have showed promising outcomes in the treatment of hepatitis B and C infections.

Regional Growth Dynamics
Based on the region, the global virus-like particles market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. 

North America dominates the global virus-like particles market with the largest revenue share. the rise in addiction rates, the prevalence of chronic diseases, the demand for vaccinations, the rising awareness of the advantages of immunization, the development of cutting-edge technologies, and government measures to encourage vaccination are attributed to North America's significant revenue share in the global market. 

Request for Customization – https://www.growthplusreports.com/inquiry/customization/virus-like-particles-market/8493

Competitive Landscape

The following companies are important players in the global virus-like particles market:

• Merck & Co., Inc.
• GlaxoSmithKline plc.
• Dynavax Technologies Corporation
• Sanofi S.A.
• Pfizer Inc.
• Wantai BioPharm
• LG Chem Ltd.
• Serum Institute of India Pvt. Ltd.
• Bharat Biotech International Limited
• VBI Vaccines Inc.

There is moderate competition in the virus-like particles market. To introduce novel drugs and products, the major players in the market emphasize research and development. Major companies often engage in mergers and acquisitions to enhance their market share.

Table of Content

1. INTRODUCTION
   1. Market Ecosystem
   2. Timeline Under Consideration
      1. Historical Years – 2021
      2. Base Year – 2022
      3. Forecast Years – 2023 to 2031
   3. Currency Used in the Report
2. RESEARCH METHODOLOGY 
   1. Research Approach
   2. Data Collection Methodology
   3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
   4. Market Estimation Approach
      1. Bottom Up
      2. Top Down 
   5. Market Forecasting Model
   6. Limitations and Assumptions
3. PREMIUM INSIGHTS
   1. Current Market Trends (COVID-19 Perspective)
   2. Key Players & Competitive Positioning (2022) 
   3. Regulatory Landscape
4. MARKET DYNAMICS
   1. Drivers
   2. Restraints/Challenges
   3. Opportunities
5. GLOBAL VIRUS LIKE PARTICLES MARKET - ANALYSIS & FORECAST, BY TYPE
   1. Vaccines
   2. Therapeutics
6. GLOBAL VIRUS LIKE PARTICLES MARKET - ANALYSIS & FORECAST, BY SOURCE
   1. Yeast
   2. Plant
   3. Insect Cell
   4. Others
7. GLOBAL VIRUS LIKE PARTICLES MARKET - ANALYSIS & FORECAST, BY APPLICATION
   1. Hepatitis
   2. Gaucher Disease
   3. Cancer/HPV
   4. Others

VIRUS LIKE PARTICLES MARKET TOC

Buy this Premium Research Report: https://www.growthplusreports.com/checkout-8493

 VALUE PROPOSITIONS RELATED TO THE REPORT:

• Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
• Comprehensive quantitative and qualitative insights at segment and sub-segment level
• Covid 19 impact trends and perspective
• Granular insights at global/regional/country level
• Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
• Blanket coverage on competitive landscape
• Winning imperatives
• Exhaustive coverage on 'Strategic Developments' registered by leading players of the market.

CUSTOMIZATION OPTIONS:

• Distributor Landscape Assessment
• Pricing Intelligence
• Customer Base Assessment
• Investment & Initiatives Analysis
• 'Business Profile' of Key Players

Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction

Visit our report store at - https://www.growthplusreports.com/report-store

Browse more latest healthcare reports:

Sympathomimetic Drugs Market by Type (Direct, Indirect, Mized), Indications (Cardiovascular Diseases, Asthma & COPD), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031

Cortisone Acetate Market by Indication (Rheumatic Diseases, Dermatologic Conditions), Route of Administration (Oral and Parenteral), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031

Belladonna Alkaloids Market by Type (Atropine, Hyoscyamine), Application (Gastrointestinal Disorders, Respiratory Disorders, Overactive Bladder), Route of Administration (Oral, Topical), End User (Hospitals, Pharmaceutical Companies)-Global Outlook & Forecast 2023-2031

Calcium Homeostasis Drugs Market by Drug Class (Calcium Metabolism Modifiers, Parathyroid Hormone Analogs), Indication (Hypocalcemia, Hypercalcemia), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031

Mirvetuximab Soravtansine Market by Indication (Ovarian Cancer, Fallopian Tube Carcinoma), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.